A Phase II Trial of De-escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
Latest Information Update: 18 Feb 2025
Price :
$35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Mycophenolate mofetil (Primary) ; Ruxolitinib (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 01 Oct 2024 Planned End Date changed from 15 Dec 2025 to 15 Sep 2025.
- 01 Oct 2024 Planned primary completion date changed from 15 Dec 2025 to 15 Sep 2025.
- 29 Aug 2023 Planned End Date changed from 15 Jul 2025 to 15 Dec 2025.